STAT News

STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease

Argenx said its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder.

By STAT News

1 min read
STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights